K. Rai

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
K R Rai, K Rai, Kanti Rai, K. R. Rai, K. Rai, Kanti R. Rai, Kanti R Rai
Publication record
503 papers · 31,860 citations · H-index 73

PAPERS

Delivery of Foreign Antigen Selectively to Membrane IgD on CLL and Normal B Cells Leads to Superior T-Cell Activation: A Possible Approach to Restore/Enhance T-Cell Immunity and T-Cell Help
20240 citationsauthor #11
The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia
20240 citationsauthor #14
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism
20242 citationsauthor #6
Normal B Cells in MBL Are Biased Toward Antigen-Experienced B Cells, with Increased Percentages of DN1 Cells in IGHV-Mutated MBL and ABC/DN2 Cells in IGHV-Unmutated MBL Suggesting Distinct Follicular/Extrafollicular Maturation Pathways
20240 citationsauthor #7
Normal B Cells in MBL Exhibit Distinct Transcriptomes Compared to Those of Healthy Individuals, Although They Differ in Activation State Based on IGHV Mutation Status
20230 citationsauthor #9
CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring
20236 citationsauthor #11
Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
20237 citationsauthor #15
Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli
20233 citationsauthor #11
Transcriptomic Analyses Indicate That Pre-Leukemic B Cells from People with Monoclonal B Lymphocytosis Are Surprisingly Much Less Active Than Normal B Cells from People with Monoclonal B Lymphocytosis and from Healthy Donors
20230 citationsauthor #10
How Do We Place Monoclonal B-cell Lymphocytosis in the Context of Early, Asymptomatic Chronic Lymphocytic Leukemia?
20230 citationsauthor #1
CLECL1+ CLL Cells: A Key Subset That Drives CLL Survival and Proliferation and Shapes a Th2-Biased Tumor Microenvironment
20221 citationsauthor #11
Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner
20221 citationsauthor #9
CD8+ T Cells from Patients with CLL Show Evidence of Granzyme B and Perforin Cytotoxic Capacity, Which Is Enhanced upon Exposure to Exogenous IL2 and/or IL21
20220 citationsauthor #10
Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners.
20224 citationsauthor #12
How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?
20228 citationsauthor #3
Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
20222 citationsauthor #14
Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL
20220 citationsauthor #15
Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.
202216 citationsauthor #8
Correction to: Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
20220 citationsauthor #14
Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
20223 citationsauthor #23
B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia
202113 citationsauthor #10
Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL
20210 citationsauthor #11
A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice
202112 citationsauthor #5
Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue
20210 citationsauthor #6
Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation
20212 citationsauthor #4
Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course
202115 citationsauthor #12
Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL
20210 citationsauthor #14
AID overexpression leads to aggressive murine CLL and non-Ig mutations that mirror human neoplasms.
202110 citationsauthor #15
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target
202127 citationsauthor #15
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL
202146 citationsauthor #18
Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in Preclinical Models
20210 citationsauthor #12
CLL-like monoclonal B cell lymphocytosis displays an increased inflammatory signature that is reduced in early stage chronic lymphocytic leukemia.
20215 citationsauthor #15
CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation.
202011 citationsauthor #9
FcgRIIb-BCR co-ligation inhibits BCR signaling in chronic lymphocytic leukemia
20200 citationsauthor #10
Phase 2 Study of the Safety and Efficacy of Umbralisib in Patients with CLL Who Are Intolerant to BTK or PI3Kδ Inhibitor Therapy.
202036 citationsauthor #8
FcγRIIb-BCR coligation inhibits B-cell receptor signaling in chronic lymphocytic leukemia
20202 citationsauthor #9
Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia
20190 citationsauthor #13
Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.
201935 citationsauthor #15
Deciphering the CXCL9-CXCL10-CXCL11/CXCR3 Axis in CLL-like Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: A New Target for Immune Activation?
20190 citationsauthor #14
IL-15-driven clonal expansion of TLR9-primed human B-CLL is characterized by activation of AKT and STAT5, downstream elevation of cyclin D2 and repression of DNA damage response mediators, ATM and TP53BP
20190 citationsauthor #6
Pathogenesis and etiology
20191 citationsauthor #1
Mechanism for IL-15–Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins
201914 citationsauthor #7
Growth dynamics in naturally progressing chronic lymphocytic leukaemia
2019104 citationsauthor #20
CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib
20192 citationsauthor #12
Molecular Analysis of FcγRIIb-BCR Colligation Signaling in Primary CLL Lymphocytes
20190 citationsauthor #8
Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options
201982 citationsauthor #2
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
20181,436 citationsauthor #12
Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia
20183 citationsauthor #13
Chronic Lymphocytic Leukemia B Cells Display IgM and IgD Isotype-Restricted Features That Affect Association with Co-Receptors, BCR Signaling, and Leukemic B-Cell Growth In Vivo
20180 citationsauthor #9
Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl
20182 citationsauthor #7
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion
201821 citationsauthor #6
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
201811 citationsauthor #13
Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue
20180 citationsauthor #5
Coordinated events following TLR-9 and CD122 signaling promote NF-kB/AKT/STAT5-dependent B-CLL clonal expansion
20180 citationsauthor #7
CLL Intraclonal Fractions Defined By Time Since Cell Birth/Division Promote a Leukemia-Supportive, Immune-Tolerant Microenvironment By Distinct Mechanisms
20180 citationsauthor #9
Augmenting NF-kappaB in poor-risk CLL : A general paradigm for other cancers ?
20183 citationsauthor #2
Dual Inhibition of PI3K-δ and PI3K-γ By Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Patient-Derived Xenograft Model
20187 citationsauthor #10
IgM and IgD Differential CLL BCRs Organization and Interaction with Co-Receptors before and during Ibrutinib Therapy
20171 citationsauthor #15
Chylothorax in Patients With Chronic Lymphocytic Leukemia: A Case Series
20175 citationsauthor #6
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
2017236 citationsauthor #28
IgM and IgD Differential CLL BCRs Organization and Interaction with Co-Receptors before and during Ibrutinib Therapy
20171 citationsauthor #16
IgM and IgD Differential CLL BCRs Organization and Interaction with Co-Receptors before and during Ibrutinib Therapy
20171 citationsauthor #17
Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
201728 citationsauthor #20
Binding of CLL Subset 4 B Cell Receptor Immunoglobulins to Viable Human Memory B Lymphocytes Requires a Distinctive IGKV Somatic Mutation
201721 citationsauthor #8
Ibrutinib Disrupts IL-4R - IL-4 Axis By Inhibiting IL-4R Signaling and Reversing Th2/Th1 Polarization through Diminished CLECL1 in CLL B Cells
20172 citationsauthor #12
Abstract 960: Mechanisms underlying primary ibrutinib sensitivity in CLL
20170 citationsauthor #6
APOBEC gene family expression and hallmarks in chronic lymphocytic leukemia
20170 citationsauthor #11
FcγRIIb expression in early stage chronic lymphocytic leukemia
20175 citationsauthor #8
Chronic lymphocytic leukaemia
2017270 citationsauthor #9
Reactive Oxygen Species and Metabolic Gene Expression Profiling Further Differentiate CXCR4/CD5 Fractions in Chronic Lymphocytic Leukemia
20170 citationsauthor #4
Frontline CLL Therapy: Changes in Paradigm
20170 citationsauthor #1
Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia
20164 citationsauthor #6
In CLL, Myeloid-Derived Suppressor Cells and Their Monocytic and Granulocytic Varieties Differ in T-Cell Subset Association and Polarization Induction
20161 citationsauthor #17
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia*
201613 citationsauthor #4
The RNA-Binding Protein Musashi 2 Is Upregulated in the Proliferative Fraction of CLL Clones, Particularly in U-CLL Patients, and Its Silencing Induces Programmed Cell Death
20160 citationsauthor #6
Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status.
201613 citationsauthor #7
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
201616 citationsauthor #10
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process.
201630 citationsauthor #12
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
2016127 citationsauthor #10
Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia
201632 citationsauthor #7
Comparative Density Analyses of B Cell Receptor-Complex Components (Membrane IgM, Membrane IgD, and Stimulatory/Inhibitory Co-Receptors) on Intraclonal Subpopulations of CLL B Cells, before and during Ibrutinib Therapy
20160 citationsauthor #9
Targeting Mutant BRAF with Vemurafenib in Relapsed or Refractory Hairy Cell Leukemia
20162 citationsauthor #23
B Cells of the Proliferative Fraction of CLL Clones Exhibit Activated B-Cell and Myeloid-Cell Signatures Suggesting Enhanced Antigen-Presentation, Integrin Responsiveness, and IL-4 Receptiveness: Additional Targets for CLL Therapy
20162 citationsauthor #9
In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment
20161 citationsauthor #9
Chronic lymphocytic leukemia (CLL)—Then and now
2016142 citationsauthor #1
A Distributed International Patient Data Registry for Hairy Cell Leukemia
20160 citationsauthor #38
The Correlation of APOBEC Gene Family Member Expression with Worse CLL Patient Outcome Suggests a Role in CLL Mutational Evolution
20152 citationsauthor #10
A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes
20152 citationsauthor #18
Cytoplasmic myosin exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability
20157 citationsauthor #11
The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones
20150 citationsauthor #6
Dual Inhibition of PI3K-Delta and Gamma By Duvelisib (IPI-145) Impairs CLL B- and T-Cell Migration, Survival and Proliferation in a Murine Xenograft Model Using Primary Chronic Lymphocytic Leukemia Cells
20158 citationsauthor #3
Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia
201533 citationsauthor #1
TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells
201553 citationsauthor #12
Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation
201512 citationsauthor #7
Characterization of Atrial Fibrillation and Bleeding Risk Factors in Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US)
20155 citationsauthor #4
Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia
20152 citationsauthor #10
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
2015278 citationsauthor #22
A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes
201519 citationsauthor #18
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes
20150 citationsauthor #7
Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers?
20155 citationsauthor #2

TIMELINE

1960 1 citations

1962 58 citations

1963 2 citations

1964 109 citations

1967 49 citations

1968 4 citations

1969 10 citations

1970 27 citations

1971 15 citations

1972 22 citations

1975 1,298 citations

1976 124 citations

1977 171 citations

1979 231 citations

1980 132 citations

1981 922 citations

1982 64 citations

1983 0 citations

1984 87 citations

1985 19 citations

1986 61 citations

1987 152 citations

1988 593 citations

1989 1 citations

1990 396 citations

1991 0 citations

1992 72 citations

1993 173 citations

1994 53 citations

1996 2,076 citations

1997 13 citations

1998 1,053 citations

1999 2,820 citations

2000 1,275 citations

2001 72 citations

2002 2,600 citations

2003 1,018 citations

2004 2,302 citations

2005 1,725 citations

2006 183 citations

2007 398 citations

2008 4,162 citations

2009 801 citations

2010 496 citations

2011 1,106 citations

2012 344 citations

2013 352 citations

2014 283 citations

2015 730 citations

2016 383 citations

2017 568 citations

2018 1,483 citations

2019 238 citations

2020 49 citations

2021 130 citations

2022 35 citations

2023 16 citations

2024 2 citations

Unknown 0 citations

K. Rai

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT